Clinical Trials Logo

Lymphoma, Malignant clinical trials

View clinical trials related to Lymphoma, Malignant.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT02916979 Completed - Multiple Myeloma Clinical Trials

Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG

FluBuATG
Start date: September 6, 2016
Phase: Phase 1
Study type: Interventional

This study is examining a chemotherapy regimen and immune suppressive medications in the setting of an allogeneic stem cell transplant. A pilot clinical trial to characterize the incidence, prevalence and function of myeloid-derived suppressor cells (MDSCs) and immune checkpoint regulators (V-domain Ig Suppressor of T-cell Activation [VISTA], cytotoxic T-lymphocyte- associated protein 4 [CTLA-4], programmed death-ligand 1 [PD-L1]) during early immune recovery following an allogeneic stem cell transplant. The site will use a myeloablative regimen of fludarabine with busulfan, adopted from CALGB 100801, to define clinical endpoints, including engraftment, 100 day survival and one year survival (Objective #1). The site will characterize the incidence, prevalence and function of MDSCs and immune checkpoint regulators in patients' blood and bone marrow following transplantation (Objective #2). The site will correlate these laboratory results with clinical outcomes and the incidence of graft-versus-host disease (GVHD). As an exploratory aim, in those patients experiencing GVHD and requiring treatment, the site will define the MDSCs frequency and checkpoint regulator expression and correlate these results with the patient's response to GVHD therapy.

NCT ID: NCT02249429 Completed - Lymphoma, Malignant Clinical Trials

Open-Label, Non Randomized Phase 2 Study With Safety Run-In

Start date: May 2015
Phase: Phase 2
Study type: Interventional

The main goal of this study is to determine the Maximum Tolerated Dose (MTD) and the Recommended Phase II Dose (RP2D) as well as preliminary antitumor activity of bimiralisib (PQR309) administered orally, as once daily capsules continuously and on intermittent schedule in patients with relapsed or refractory lymphomas.

NCT ID: NCT01432951 Completed - Solid Tumor Clinical Trials

A Study of Enzastaurin in Chinese Patients With Advanced and/or Metastatic Solid Tumors or Lymphoma

Start date: November 2011
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the pharmacokinetics (PK) of enzastaurin and its metabolites in native Chinese participants with advanced and/or metastatic solid tumors or lymphoma. Information about any side effects that may occur will also be collected. Treatment of disease is not the main purpose of the study. This is a Phase 1 study of enzastaurin in native Chinese participants with advanced and/or metastatic solid tumors or lymphoma. Participants will receive daily doses of enzastaurin for 14 days, stop dosing for 3 days during PK sampling, and resume dosing on Day 18. Participants may be allowed to receive enzastaurin for approximately 2 to 4 weeks after day 18 to provide an opportunity for a participant's oncologist to assess the potential benefit of the participant continuing to receive enzastaurin in the safety extension phase. There is no planned duration for the extension phase; participants are allowed to continue receiving enzastaurin until disease progression or other reason for discontinuation as per the investigator's assessment.

NCT ID: NCT01388335 Completed - Solid Tumor Clinical Trials

A Drug Interaction Study to Assess the Effect of LY317615 on the Metabolic Pathway of Warfarin

Start date: August 2011
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the effect of enzastaurin (LY317615), on a protein (enzyme CYP2C9) which is involved in the metabolic pathway of warfarin in participants with solid tumors or lymphomas. Information about any side effects that may occur will also be collected. This is a drug interaction study so the treatment of the disease will not be the main purpose of the study. This is a Phase 1, open label, fixed sequence, 2 period study conducted in participants with solid tumors or lymphomas. The duration of participation in this study will be up to approximately 38 days not including screening, after which participants will be allowed to continue receiving enzastaurin. There is no planned duration for the extension phase of this study; participants will be allowed to continue to receive enzastaurin until fulfilling one of the criteria for discontinuation, such as unacceptable toxicity or disease progression.

NCT ID: NCT00741871 Completed - Hodgkin's Lymphoma Clinical Trials

A Phase 1 Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies

Start date: July 2008
Phase: Phase 1
Study type: Interventional

This is a Phase 1 dose escalation study to determine the maximum tolerated dose and the dose limiting toxicities of SB1518 when given alone once daily by mouth to subjects with advanced lymphoid malignancies.

NCT ID: NCT00600353 Completed - Lymphoma, Malignant Clinical Trials

Multi-day Doses in Prevention of Nausea and Emesis

Start date: October 2007
Phase: Phase 2
Study type: Interventional

To assess emetic responses to multi-day doses of Palonosetron and Aprepitant and low dose dexamethasone +/- Prochlorperazine among patients with multiple myeloma and lymphoma undergoing autologous HSCT utilizing the Multinational Association for Supportive Care in Cancer (MASCC) Antiemesis Tool (MAT).

NCT ID: NCT00509184 Completed - Lymphoma, Malignant Clinical Trials

Rituximab and Involved Field Radiotherapy in Early Stage Follicular Lymphoma

MIR
Start date: March 2008
Phase: Phase 2
Study type: Interventional

Combination of involved field radiotherapy for the control of macroscopic disease and CD20 antibody Rituximab for the control of microscopic remainders in other regions in patients with early stage nodal follicular lymphoma /grade I or II). Evaluation of DFSl and toxicity.

NCT ID: NCT00146055 Completed - Clinical trials for Myelodysplastic Syndromes

Low-Intensity Preparation and Allogeneic Transplant in Patients With Cancers of the Blood

Start date: March 2000
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether a less-intensive preparative therapy followed by an allogeneic peripheral stem cell transplantation will provide an effective treatment for your disease and whether it will be associated with fewer side effects.

NCT ID: NCT00078637 Completed - Neoplasms Clinical Trials

Dosing and Safety Study of E7820 in Patients With a Malignant Solid Tumor or Lymphoma

Start date: January 2004
Phase: Phase 1
Study type: Interventional

This is a first-in-man, open-label, non-randomized, multiple dose, multiple cycle, dose escalation study to determine the MTD, safety, PK, and pharmacodynamics of E7820 in patients with a malignant solid tumor or lymphoma.

NCT ID: NCT00037791 Completed - Multiple Myeloma Clinical Trials

Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia

Start date: December 1999
Phase: Phase 3
Study type: Interventional

Intensive chemotherapy is associated with significant thrombocytopenia, often requiring platelet transfusion to maintain platelet counts. This investigational drug has demonstrated the ability to increase platelet counts. This study will test the safety and efficacy of this investigational drug in the prevention of thrombocytopenia in patients with solid tumors, lymphomas or multiple myeloma who are receiving myelosuppressive treatment regimens requiring platelet transfusion support.